MSFT   207.07 (-3.09%)
FB   239.00 (-2.48%)
GOOGL   1,512.23 (-1.74%)
AMZN   3,104.00 (-3.00%)
NVDA   402.09 (-4.07%)
CGC   17.30 (-0.69%)
BABA   251.67 (-3.58%)
MU   49.46 (-2.45%)
GE   6.70 (+0.15%)
TSLA   1,497.06 (-3.08%)
AMD   53.59 (-4.10%)
T   29.76 (-1.23%)
F   6.06 (-0.66%)
GILD   76.68 (+0.47%)
NFLX   525.50 (-4.23%)
BAC   24.19 (+0.71%)
MSFT   207.07 (-3.09%)
FB   239.00 (-2.48%)
GOOGL   1,512.23 (-1.74%)
AMZN   3,104.00 (-3.00%)
NVDA   402.09 (-4.07%)
CGC   17.30 (-0.69%)
BABA   251.67 (-3.58%)
MU   49.46 (-2.45%)
GE   6.70 (+0.15%)
TSLA   1,497.06 (-3.08%)
AMD   53.59 (-4.10%)
T   29.76 (-1.23%)
F   6.06 (-0.66%)
GILD   76.68 (+0.47%)
NFLX   525.50 (-4.23%)
BAC   24.19 (+0.71%)
MSFT   207.07 (-3.09%)
FB   239.00 (-2.48%)
GOOGL   1,512.23 (-1.74%)
AMZN   3,104.00 (-3.00%)
NVDA   402.09 (-4.07%)
CGC   17.30 (-0.69%)
BABA   251.67 (-3.58%)
MU   49.46 (-2.45%)
GE   6.70 (+0.15%)
TSLA   1,497.06 (-3.08%)
AMD   53.59 (-4.10%)
T   29.76 (-1.23%)
F   6.06 (-0.66%)
GILD   76.68 (+0.47%)
NFLX   525.50 (-4.23%)
BAC   24.19 (+0.71%)
MSFT   207.07 (-3.09%)
FB   239.00 (-2.48%)
GOOGL   1,512.23 (-1.74%)
AMZN   3,104.00 (-3.00%)
NVDA   402.09 (-4.07%)
CGC   17.30 (-0.69%)
BABA   251.67 (-3.58%)
MU   49.46 (-2.45%)
GE   6.70 (+0.15%)
TSLA   1,497.06 (-3.08%)
AMD   53.59 (-4.10%)
T   29.76 (-1.23%)
F   6.06 (-0.66%)
GILD   76.68 (+0.47%)
NFLX   525.50 (-4.23%)
BAC   24.19 (+0.71%)
Log in

NASDAQ:EVFMEvofem Biosciences Stock Price, Forecast & News

$2.97
-0.11 (-3.57 %)
(As of 07/13/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.93
Now: $2.97
$3.16
50-Day Range
$2.78
MA: $3.61
$5.93
52-Week Range
$2.73
Now: $2.97
$7.50
Volume3.11 million shs
Average Volume3.68 million shs
Market Capitalization$147.64 million
P/E RatioN/A
Dividend YieldN/A
Beta0.41
Evofem Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. Its lead product candidate is Amphora, a non-hormonal woman-controlled vaginal gel, which is in Phase 3 clinical trial for the prevention of pregnancy; and in Phase 2b trial for the prevention of chlamydia and gonorrhea in women. The company is also developing multi-purpose vaginal pH regulator gel product candidate for the reduction of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Read More
Evofem Biosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.37 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EVFM
CUSIPN/A
Phone858-550-1900

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.33 per share

Profitability

Net Income$-80,030,000.00

Miscellaneous

Employees30
Market Cap$147.64 million
Next Earnings Date8/3/2020 (Estimated)
OptionableNot Optionable

Receive EVFM News and Ratings via Email

Sign-up to receive the latest news and ratings for EVFM and its competitors with MarketBeat's FREE daily newsletter.

Evofem Biosciences (NASDAQ:EVFM) Frequently Asked Questions

How has Evofem Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Evofem Biosciences' stock was trading at $5.16 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, EVFM shares have decreased by 42.4% and is now trading at $2.97. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Evofem Biosciences?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evofem Biosciences in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Evofem Biosciences.

When is Evofem Biosciences' next earnings date?

Evofem Biosciences is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Evofem Biosciences.

How were Evofem Biosciences' earnings last quarter?

Evofem Biosciences Inc (NASDAQ:EVFM) posted its quarterly earnings data on Wednesday, May, 6th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.32) by $0.08. View Evofem Biosciences' earnings history.

What price target have analysts set for EVFM?

5 brokerages have issued 1 year target prices for Evofem Biosciences' shares. Their forecasts range from $6.00 to $25.00. On average, they anticipate Evofem Biosciences' stock price to reach $12.00 in the next year. This suggests a possible upside of 304.0% from the stock's current price. View analysts' price targets for Evofem Biosciences.

Has Evofem Biosciences been receiving favorable news coverage?

Headlines about EVFM stock have trended very negative recently, according to InfoTrie Sentiment. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Evofem Biosciences earned a media sentiment score of -3.2 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about Evofem Biosciences.

Who are some of Evofem Biosciences' key competitors?

What other stocks do shareholders of Evofem Biosciences own?

Who are Evofem Biosciences' key executives?

Evofem Biosciences' management team includes the following people:
  • Ms. Saundra Pelletier, CEO & Director
  • Mr. Justin J. File, Chief Financial Officer (Age 49)
  • Dr. Kelly Culwell, Chief Medical Officer
  • Mr. Jason Abrams, Accounting Mang.
  • Mr. Alexander A. Fitzpatrick, Exec. VP, Gen. Counsel & Sec. (Age 52)

What is Evofem Biosciences' stock symbol?

Evofem Biosciences trades on the NASDAQ under the ticker symbol "EVFM."

How do I buy shares of Evofem Biosciences?

Shares of EVFM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Evofem Biosciences' stock price today?

One share of EVFM stock can currently be purchased for approximately $2.97.

How big of a company is Evofem Biosciences?

Evofem Biosciences has a market capitalization of $147.64 million. The biotechnology company earns $-80,030,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis. Evofem Biosciences employs 30 workers across the globe.

What is Evofem Biosciences' official website?

The official website for Evofem Biosciences is www.evofem.com.

How can I contact Evofem Biosciences?

Evofem Biosciences' mailing address is 12400 HIGH BLUFF DRIVE SUITE 600, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-550-1900 or via email at [email protected]

This page was last updated on 7/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.